124
Views
34
CrossRef citations to date
0
Altmetric
Original Research

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

, , , , &
Pages 437-444 | Published online: 21 Feb 2011

References

  • StathopoulosGPBoulikasTVougioukaMRigatosiSKStathopoulosJGLiposomal CDDP combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I–II studyOncol Rep2006151201120416596187
  • XiaoCQiXRMaitaniYNagaiTSustained release of CDDP from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinomaJ Pharma Sci200493711491157
  • BurgerKNJStaffhorstRWHMVijlderHECDNanocapsules: lipid-coated aggregates of CDDP with high cytotoxicityNat Med200281818411786911
  • RamachandranSQuiwtAPKumarSLalRCDDP nanoliposomes for cancer therapy: AFM and fluorescence imaging of CDDP encapsulation, stability, cellular uptake, and toxicityLangmuir2006228156816216952256
  • HanIKimOJLeeGYSungYKSongRSohnYEnhanced anti-tumor activity of trans (1,2-Diaminocyclohexaneglutamatoplatinum (II)) formulated with stealth liposomeBioorg Med Chem2003115443544714642589
  • RosenthalDIYomSSLiuLA Phase I study of SPI-077 (Stealth liposomal CDDP) concurrent with radiation therapy for locally advanced head and neck cancerInvest New Drugs20022034334912201498
  • KoukourakisMICoukourakiSGiatromanolakiALiposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancerJ Clin Oncol1999173512352110550149
  • HuangSKLeeKDHongKFriendDSPapahadjopoulosDMicroscopic localization of sterically stabilized liposomes in colon carcinoma-bearing miceCancer Res199252513551431394121
  • SzokaFPapahadjopoulosDProcedure for preparation of liposomes with large internal aqueous space and high capture by reverse–phase evaporationProc Natl Acad Sci197875941944198279908
  • BurgerKNStaffhorstRWVelinovaMJNanocapsules: lipid-coated aggregates of CDDP with high cytotoxicityNat Med200281818411786911
  • Carvalho JúniorADVieiraFPde MeloVJPreparation and cytotoxicity of CDDP-containing liposomesBraz J Med Biol Res20074081149115717665053
  • JiaWGaoWYNew Formulations of Drug Controlled ReleaseBeijingChemical Industry Press2005313
  • RamachandranSQuistAPKumarSCDDP nanoliposomes for cancer therapy: AFM and fluorescence imaging of CDDP encapsulation, stability, cellular uptake, and toxicityLangmuir200622198156816216952256
  • JoschkoMAWebsterLKBishopJFRadioenhancement by CDDP with accelerated fractionated radiotherapy in a human tumour xenograftCancer Chemother Pharmacol19974065345399332470
  • LuQBMolecular reaction mechanisms of combination treatment of low-dose cisplatin with radiotherapy and photodynamic therapyJ Med Chem2007502601260417474733
  • LuQBKalantariSWangCRElectron transfer reaction mechanism of cisplatin with DNA at the molecular levelMol Pharmaceutics200744624628
  • Schaake-KoningCvan den BogaertWDalesioOEffects of concomitant CDDP and radiotherapy on inoperable non-small cell lung cancerN Engl J Med19923265245301310160
  • HarringtonKJRowlinson-BuszaGSyrigosKNPegylated liposome-encapsulated doxorubicin and CDDP enhance the effect of radiotherapy in a tumor xennograft modelClin Cancer Res200064939494911156255
  • NingSYuNBrownDMKanekalSKnoxSJRadiosensitization by intratumoral administration of CDDP in a sustained-release drug delivery systemRadiother Oncol19995021522310368046
  • ZhangXMGeYQJiangGLPharmacokinetics of CDDP packaged in a nanometer liposomeChina Oncol20071711715718
  • DoupleEBEatonWLTullohMESkin radiosensitization studies using combined cis-dichlorodiammineplatinum (II) and radiationInt J Radiat Oncol Biol Phys19795813831385575125
  • MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
  • MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287
  • VaseyPAKayeSBMorrisonRPhase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II CommitteeClin Cancer Res19995183949918206